DDInter970 DDInter1180
Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol] was approved in 1996.[L5894, L5891]
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Ipratropium {u} (Compound) resembles {v} (Compound) Methylphenidate
Ipratropium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Ipratropium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atropine
Ipratropium {u} (Compound) treats {v} (Disease) asthma
Ipratropium {u} (Compound) binds {v} (Gene) SLC22A4
Ipratropium {u} (Compound) upregulates {v} (Gene) UBQLN2
Ipratropium {u} (Compound) downregulates {v} (Gene) RPS4Y1
Ipratropium {u} (Compound) causes {v} (Side Effect) Flu symptoms
Ipratropium {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hyoscyamine
Ipratropium (Compound) resembles Methylphenidate (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Trospium
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Atropine
Ipratropium (Compound) treats asthma (Disease)
Ipratropium (Compound) binds SLC22A4 (Gene)
Ipratropium (Compound) upregulates UBQLN2 (Gene)
Ipratropium (Compound) downregulates RPS4Y1 (Gene)
Ipratropium (Compound) causes Flu symptoms (Side Effect)
Ipratropium (Compound) resembles Hyoscyamine (Compound) and Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine